Mutual Funds Commodities Research Tax Planning IPO Our Team Contact Us  
Google
Web www.equitybulls.com
Stock Report

| More

Zydus Cadila announces USFDA approval for First Generic for Ibrutinib Capsules, 70 mg and gets eligibility for 180-day exclusivity

Posted On: 2021-04-07 21:49:22 (Time Zone: Arizona, USA)


Zydus Cadila has received final approval from the USFDA to market Ibrutinib Capsules, 70 mg and 140 mg (US RLD: Imbruvica Capsules). Ibrutinib belongs to a class of drugs known as kinase inhibitors and is used to treat certain cancers, such as mantle cell lymphoma or marginal zone lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma, and Waldenstrom's macroglobulinemia.

According to the USFDA letter, Zydus was the first ANDA applicant to submit a substantially complete ANDA with a paragraph IV certification for Ibrutinib Capsules, 70 mg. Therefore, with this approval, Zydus is eligible for 180 days of generic drug exclusivity for Ibrutinib Capsules, 70 mg. For Ibrutinib Capsules, 140 mg, the company will have 180-days of shared generic drug exclusivity. The 70 mg capsule has brand sales of USD 32.5 mn, while the 140 mg dose has brand sales of USD 745.9 mn. Zydus is the first company to receive approval for generic Ibrutinib 70 mg capsules.

Managing Director, Zydus Group, Dr. Sharvil Patel commented, "This FDA approval of Ibrutinib Capsules reinforces our long-term commitment to provide patients and caregivers access to affordable therapies. We have been investing significantly in building a portfolio of complex generic products and leveraging capabilities that will help us successfully commercialize and gain meaningful market share in the complex generic products and difficult-to-manufacture generic products. We have created a diversified portfolio of over 50 filed complex ANDAs seeking USFDA approval and we will continue to expand this as we explore opportunities to grow our US business in 2021 and beyond."

The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 313 approvals and has so far filed over 400 ANDAs since the commencement of the filing process in FY 2003-04.

Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.461.25 as compared to the previous close of Rs. 456.8. The total number of shares traded during the day was 269845 in over 5797 trades.

The stock hit an intraday high of Rs. 464.5 and intraday low of 454.15. The net turnover during the day was Rs. 124280346.


Source: Equity Bulls

Click here to send ur comments or to feedback@equitybulls.com


Other Headlines:

Trident Ltd celebrating Mission Day with a special discount coupon to shareholders

S.P. Capital Financing Ltd approves selling of shares in Pride And Expert Properties Private Limited

IIFL Securities Limited to acquire Category II AIF from IIFL Wealth Management Ltd

HDFC Bank Limited to raise up to Rs. 50,000 crore

Indo Asian Finance Ltd to consider allotment of 60 lakh shares on April 20, 2021

KEC International Limited Resumption of WKTL Transmission Project

IIFL Wealth Management Ltd to sell AIF Category-II business to IIFL Management Services Ltd

International Travel House Ltd Q4FY21 loss at Rs. 6.70 crore

Gujarat Hotels Ltd Q4FY21 net profit slides YoY, QoQ

ICICI Lombard General Insurance Company Limited board recommends final dividend of Rs. 4

Gujarat Hotels Ltd board recommends dividend of Rs. 1.80 for FY21

ICICI Lombard General Insurance Company Ltd reports Rs. 345.68 crore PAT in Q4FY21

HDFC Bank Ltd's gross NPAs at 1.32%, reduces QoQ

HDB Financial Services Ltd's gross NPAs at 3.9% as of March 31, 2021

HDFC Securities Ltd reports PAT of Rs. 253.1 crore in Q4FY21

Career Point signed MOU with Ministry of Social Justice and Empowerment for tutorial services

HDFC Bank's balance sheet increases 14.1% YoY

Indiamart arm to acquire 22% in Truckhall Pvt Ltd

HDFC Bank Ltd Q4FY21 consolidated net profit slips QoQ to Rs. 8433.78 crore

CRISIL downgrades rating of PVR Ltd

Hatsun Agro Product Ltd board to consider FY21 results on April 27, 2021

Choice International Limited allots 34,49,989 Equity Shares on Conversion of Warrants

Adani Renewable Energy Holding Fifteen Ltd receives 159 MWac solar power project

Coforge Limited board approves issue of NCDs for Rs. 340 crore

Glenmark Life Sciences Ltd files DRHP with SEBI for IPO

KDDL Limited extends rights issue closure date to May 3, 2021

SG Shinagawa Refractories India Private Limited commences commercial operation

Prestige Estates Projects Limited acquires stake in companies having land bank in North Bangalore

ABB Power Products and Systems India Ltd board to announce Q1CY2021 results on May 5, 2021

GE Power India Limited signs SPA with GE Power Systems GmbH

Carborundum Universal Ltd board to approve final dividend and FY21 results on April 28, 2021

PNB Housing Finance Ltd board to consider FY21 results, dividend and NCD issue on April 27, 2021

ESAF Small Finance Bank raises Rs 162 Cr through preferential allotment

Everything Summer - Bahamas launches new Spring Summer collection 2021

MCX and Nihilent Technologies partners with Times OOH

44 meritorious students benefit from Vedanta's Utkarsh Scholarship awarded in presence of Goa CM

Robot-Assisted Cancer Surgery Unit Launched in Apollo Proton Cancer Centre

IndiGo is the leader in COVID vaccine distribution in the country over the last three months

Peter England launches 'The Antiviral* Linen Project' with new brand campaign 'Easy On You'

Den Networks Ltd Q4FY21 consolidated PAT drops QoQ to Rs. 36.98 crore

Isgec Heavy Engineering, United Conveyor Corporation sign agreement

Mindtree Ltd posts consolidated of Rs. 317.3 crore in Q4FY21

Government of Ghana to takeover ownership of AirtelTigo Joint Venture

ICRA retains ratings of Nahar Industrial Enterprises Ltd

NTPC to issue Non-Convertible Bonds

CRISIL retains rating of NGL Fine-Chem Ltd

GTPL Hathway's Consolidated FY21 PAT at ₹ 1,885 million, up by 145%

DCB Bank Limited receives RBI nod for reappointment of Mr. Murali M. Natrajan as MD & CEO

Mindtree Ltd Board approves final dividend of Rs. 17.50

RITES consortium emerges L1 in Railway project in Bangladesh


Website Created & Maintained by : Chennai Scripts
West Mambalam, Chennai - 600 033,
Tamil Nadu, India

disclaimer copyright © 2005 - 2020